ARTICLE | Clinical News
Lomitapide regulatory update
May 7, 2012 7:00 AM UTC
FDA accepted for review an NDA from Aegerion for lomitapide to treat homozygous familial hypercholesterolemia (HoFH). The PDUFA date is Dec. 29. In March, FDA informed the company that the compound wo...